Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00688376 · ClinicalTrials.gov registry record · Phase 3
Efficacy and Safety of Donepezil Hydrochloride in Preadolescent and Adolescent Children With Attention Impairment Following Cancer Treatment
A Phase 3 study, sponsored by Eisai.
- Completed
- Registry status
- Phase 3
- Development phase
- 72
- Enrollment target
NCT00688376 is a Phase 3 study that has completed, run by Eisai. The registered enrollment target is 72 participants.
The verdict
NCT00688376, a Phase 3 study, has completed, sponsored by Eisai.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 72 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the efficacy, safety and tolerability of donepezil in children with persistent attention impairment that is present at least 12 months after the completion of cancer treatment.
Interventions
- DRUG Placebo
- DRUG Donepezil hydrochloride
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 72 participants |
| Start Date | 2008-07-02 |
| Est. Completion | 2009-05-26 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00688376
The ClinicalTrials.gov registry entry for NCT00688376 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 72 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eisai, which has 287 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00688376 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00688376 about?
NCT00688376 is a clinical study titled "Efficacy and Safety of Donepezil Hydrochloride in Preadolescent and Adolescent Children With Attention Impairment Following Cancer Treatment". The purpose of this study is to evaluate the efficacy, safety and tolerability of donepezil in children with persistent attention impairment that is present at least 12 months after the completion of cancer treatment.
What is the current status of trial NCT00688376?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 72 participants. The study started on 2008-07-02. Estimated completion is 2009-05-26.
What interventions are being tested in trial NCT00688376?
The interventions under investigation include: Placebo (DRUG), Donepezil hydrochloride (DRUG).
Who is sponsoring clinical trial NCT00688376?
This trial is sponsored by Eisai, which has 287 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.